BIOMAT Database Logo BIOMAT Database Logo

Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. 1997

Y Imai, and W H Busby, and C E Smith, and J B Clarke, and A J Garmong, and G D Horwitz, and C Rees, and D R Clemmons
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill 27599-7170, USA.

IGFs are pleiotrophic mitogens for porcine smooth muscle cells (pSMC) in culture. The effects of IGFs on cells are modulated by various insulin-like growth factor-binding proteins (IGFBP). IGFBP-5 is synthesized by pSMC and binds to the extracellular matrix. However, IGFBP-5 is also secreted into conditioned medium of cultured cells and is cleaved into fragments by a concomitantly produced protease. These fragments have reduced affinity for the IGFs and cleavage makes it difficult to assess the role of intact IGFBP-5. To study the consequence of accumulation of intact IGFBP-5 in medium, we determined the cleavage site in IGFBP-5 and prepared a protease resistant mutant. Amino acid sequencing of purified IGFBP-5 fragments suggested Arg138-Arg139 as the primary cleavage site. Arg138-Arg139-->Asn138-Asn139 mutations were introduced to create protease-resistant IGFBP-5, which has the same affinity for IGF-I as the native protein. This mutant IGFBP-5 remained intact even after 24 h of incubation and it inhibited several IGF-I actions when added to pSMC culture medium. The mutant IGFBP-5 (500 ng/ml) decreased IGF-I stimulated cellular DNA synthesis by 84%, protein synthesis by 77%, and it inhibited IGF-I stimulated migration of pSMC by 77%. It also inhibited IGF-I stimulation of IRS-1 phosphorylation. In contrast, the same amount of native IGFBP-5 did not inhibit IGF-I actions. The significance of inhibitory effects of the protease resistant IGFBP-5 was further demonstrated in pSMC transfected with mutant or native IGFBP-5 cDNAs. The mutant IGFBP-5 accumulated in culture medium of transfected cells, while native IGFBP-5 was degraded into fragments, PSMC overexpressing the mutant IGFBP-5 also responded poorly to IGF-I compared with mock transfected cells. IGF-I (5 ng/ml) increased [35S]methionine incorporation into control cells by 36% above the basal level, but it did not significantly change (4%) in pSMC cultures that were producing the mutant IGFBP-5. In conclusion, the accumulation of protease-resistant IGFBP-5 in the medium was inhibitory to IGF-I actions on pSMC. This suggests that proteolysis can prevent IGFBP-5 from acting as an inhibitor of IGF-I-stimulated effects and that it serves as an important mechanism for regulating cellular responsiveness to IGF-I.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008666 Metalloendopeptidases ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism. Metallo-Endoproteinases,Metalloendopeptidase
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Y Imai, and W H Busby, and C E Smith, and J B Clarke, and A J Garmong, and G D Horwitz, and C Rees, and D R Clemmons
Porcine aortic smooth muscle cells secrete a serine protease for insulin-like growth factor binding protein-2.
April 1995, Circulation research,
Y Imai, and W H Busby, and C E Smith, and J B Clarke, and A J Garmong, and G D Horwitz, and C Rees, and D R Clemmons
Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells.
June 1995, Endocrinology,
Y Imai, and W H Busby, and C E Smith, and J B Clarke, and A J Garmong, and G D Horwitz, and C Rees, and D R Clemmons
A protease-resistant form of insulin-like growth factor (IGF) binding protein 4 inhibits IGF-1 actions.
October 1998, Endocrinology,
Y Imai, and W H Busby, and C E Smith, and J B Clarke, and A J Garmong, and G D Horwitz, and C Rees, and D R Clemmons
Control of insulin-like growth factor binding protein-5 protease synthesis and secretion by human fibroblasts and porcine aortic smooth muscle cells.
June 2003, Endocrinology,
Y Imai, and W H Busby, and C E Smith, and J B Clarke, and A J Garmong, and G D Horwitz, and C Rees, and D R Clemmons
7S nerve growth factor is an insulin-like growth factor-binding protein protease.
July 1996, Endocrinology,
Y Imai, and W H Busby, and C E Smith, and J B Clarke, and A J Garmong, and G D Horwitz, and C Rees, and D R Clemmons
Protease-resistant insulin-like growth factor (IGF)-binding protein-4 inhibits IGF-I actions and neointimal expansion in a porcine model of neointimal hyperplasia.
October 2007, Endocrinology,
Y Imai, and W H Busby, and C E Smith, and J B Clarke, and A J Garmong, and G D Horwitz, and C Rees, and D R Clemmons
Insulin-like growth factor binding protein production by bovine and human vascular smooth muscle cells: production of insulin-like growth factor binding protein-6 by human smooth muscle.
December 1996, Endocrinology,
Y Imai, and W H Busby, and C E Smith, and J B Clarke, and A J Garmong, and G D Horwitz, and C Rees, and D R Clemmons
Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I.
July 1997, Endocrinology,
Y Imai, and W H Busby, and C E Smith, and J B Clarke, and A J Garmong, and G D Horwitz, and C Rees, and D R Clemmons
Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism.
August 1994, The American journal of physiology,
Y Imai, and W H Busby, and C E Smith, and J B Clarke, and A J Garmong, and G D Horwitz, and C Rees, and D R Clemmons
Insulin-like growth factor binding protein-5 modulates muscle differentiation through an insulin-like growth factor-dependent mechanism.
May 1996, The Journal of cell biology,
Copied contents to your clipboard!